ClinicalTrials.gg
Active, not recruitingNCT04898543Updated Nov 2, 2026

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B) and N-803 (Cohort 2 part B) in Metastatic Solid Tumor, sponsored by ImmunityBio, Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by ImmunityBio, Inc. · Phase 1, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Neoplasm Metastasis by ImmunityBio, Inc. — none open to participants now, 1 under way, none of them phase 3. Neoplasm Metastasis · ImmunityBio, Inc..

Planned enrollment
9th of 18
50 · median 40
Started
2021
the only one that year
Phase 1
7 of 18
none open now
Registered
18th of 18
by date

Among the 18 studies in Neoplasm Metastasis by ImmunityBio, Inc., this one is the 9th largest by planned enrollment, is the only one that started in 2021, is one of 7 in phase 1, and was the 18th registered.

Neoplasm Metastasis

4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

None of the 18 studies in Neoplasm Metastasis by ImmunityBio, Inc. is open now. The open studies under Neoplasm Metastasis, anywhere →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Neoplasm Metastasis by ImmunityBio, Inc. as a file.
02

Study summary

This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic solid tumors. The study consists of two cohorts: cohort 1 includes subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment; and cohort 2 that includes subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies. The two cohorts will be conducted simultaneously.

Read the detailed description

Both cohorts will be enrolled simultaneously. Both cohorts have a part A (apheresis) and cohort 2 has a part B (M-CENK treatment [one bag has a 100 mL cell suspension containing 0.25 to 0.75 x 109 cells] and N-803 treatment).

Up to 40 subjects may be enrolled in cohort 1. Subjects in cohort 1 will participate in apheresis collection of MNCs prior to receiving disease specific first-line therapy per primary oncologists' recommendations. Subjects who have completed apheresis in cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy.

They must also meet the inclusion criteria to participate in the treatment phase (cohort 2 part B). Additionally, all subjects will be re-evaluated to confirm that they still meet the specified eligibility criteria once the M-CENK cells are manufactured and prior to the first administration of M-CENK. The Sponsor will approve the subject's continued eligibility prior to receiving the manufactured M-CENK cells.

Up to 21 subjects may be enrolled in cohort 2 part A so that up to 11 subjects receive at least 1 dose of M-CENK. A dose is a single administration of M-CENK cells or a single administration of N-803. Subjects in cohort 2 part A will undergo an apheresis collection of MNCs prior to receiving approximately 4 weeks of disease-specific therapy per oncologists' recommendations while the M-CENK cells are being manufactured for use in the treatment phase (cohort 2 part B). Subjects will be evaluated for eligibility in inclusion/exclusion criteria prior to enrollment into part B. Additionally, all subjects will be re-evaluated to confirm that they still meet the specified eligibility criteria once the M-CENK cells are manufactured and prior to the first administration of M-CENK. The Sponsor will approve the subject's continued eligibility prior to receiving the manufactured M-CENK cells.

M-CENK cells, manufactured from the autologous apheresis product, may be administered up to 10 times weekly starting on study day 1 with a minimum of 7 days between each M-CENK dose depending on the availability of cells and that there is no contra-indication to administer cells. Subjects will receive up to 5 doses of N-803 SC every 2 weeks prior to every other dose of M-CENK (ie, odd number M-CENK doses).The treatment may be administered for up to 10 doses of M-CENK, if the subject tolerates treatment, the doses of M-CENK cells are available, and the Investigator believes there may be potential benefit to the subject.

Safety endpoints include assessments of TEAEs, SAEs, and clinically significant changes in safety laboratory tests, and vital signs. Toxicities will be graded using CTCAE Version 5.0, or in the case of CRS, using a specified grading system. Safety will be monitored throughout the study.

The treatment of the initial 3 subjects in cohort 2 part B will be staggered with at least a 2-week interval between each subject. After the first 3 subjects in cohort 2 part B are treated, the treatment of existing subjects in cohort 2 part B will be paused after the 14-day toxicity assessment period for a safety evaluation by the Safety Review Committee (SRC). Based on the SRC safety evaluation, the treatment of the subsequent subjects can proceed if the safety evaluation from the initial 3 subjects in part B suggests that the therapy is safe. There will be another safety review after all subjects in cohort 2 have completed the 14-day toxicity assessment period.

03

Conditions studied

  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Cohorts 1 and 2, Part A:

  • Age ≥ 18 years old.
  • Able to understand and provide a signed that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  • Have confirmed locally advanced, unresectable, or solid tumor.
  • For subjects with genetic mutations or alterations in solid tumors (e.g. NSCLC, pancreatic cancer, melanoma), the subjects must have received prior appropriate disease specific targeted therapy and have progressed.
  • Have at least 1 and/or non-measurable disease evaluable in accordance with Version 1.1.
  • For subjects with a history of (HIV)
  • Subjects with CD4+ T-cell (CD4+) counts ≥ 350 cells/uL and without a history of AIDS defining opportunistic infections.
  • For subjects with a history of virus (HBV)
  • Subjects who are chronic carriers of HBV infection (HBsAg-positive, undetectable or low HBV DNA, and normal ) who are not on HBV therapy, or in individuals who have serologic evidence of a resolved prior HBV infection (i.e., HBsAg-negative and anti-HBc-positive), anti-HBV prophylaxis should be assessed prior to enrollment.
  • Subjects with chronic HBV infection with active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy prior to enrollment.
  • For subjects with a history of virus (HCV)
  • Subjects with a history of HCV infection should have completed curative antiviral treatment and have a HCV viral load below the limit of quantification are eligible.
  • Subjects who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible.
  • Subjects on concurrent HCV treatment and have HCV below the limit of quantification are eligible.

Note: Subjects who have a history of HIV/HBV/HCV or are seropositive will require Infectious Disease Marker (IDM) testing prior to apheresis collection.

  • Subjects who currently have non-progressive and were previously treated with surgical resection/debulking, radiation, and stereotactic radiosurgery.
  • Able to undergo an Apheresis procedure:
  • Have adequate venous access
  • Able to sit or recline for 5-6 hours with limited movement
  • must be ≥ 9.0 g/dL
  • count must be ≥ 100,000 cells/mm3
  • Vital signs must be within normal range
  • Negative serum pregnancy test for females of .
  • (ECOG) performance status of 0 to 2.
  • Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  • Agreement to practice effective for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 30 days after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 30 days after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, and intrauterine devices (IUDs).

Cohort 2, Part B subjects only:

  • Have documented progressive disease after receiving treatment with at least 2 or not be a candidate for therapy of proven efficacy for their disease. Prior immune therapy and prior treatment with a as per FDA indication for current standard of care therapy is allowed.
  • Subjects cannot receive M-CENK before a 14-day following treatment with an approved chemotherapy and approved or immunotherapy (eg PD-1/PD-L1 inhibitors, CAR NK cells [PD-L1 t-haNK], N-803). A repeat lab at least 14 days after completion of the washout period is required.
  • Subjects cannot receive M-CENK before a 30-day washout period following treatment with investigational chemotherapy. A repeat lab at least 30 days after completion of the washout period is required.
  • Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  • Agreement to practice effective contraception for female subjects of child-bearing potential and nonsterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 30 days after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 30 days after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, and intrauterine devices (IUDs).

Exclusion Criteria (Cohorts 1 and 2, Part A):

There is no exclusion criteria for cohorts 1 and 2, part A.

Exclusion Criteria (Cohort 2, Part B only):

*Note: All subjects must meet eligibility criteria at the time of enrollment. Additionally, all subjects will be re-evaluated to confirm that they still meet the eligibility criteria specified with an asterisk below once the M-CENK cells are manufactured and prior to to the first administration of M-CENK. The Sponsor will approve the subject's continued eligibility prior to receiving the manufactured M-CENK cells.

  • * \< 16 weeks based on the best judgment of the Investigator.
  • *Involuntary weight loss of > 10% usual body weight between the time of enrollment and at the time of administration of M-CENK cells
  • *Calorie or protein restrictive dietary regimen.
  • *Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment- related complications.
  • Systemic disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma) requiring medical treatment.
  • *Currently receiving or has received antibiotics since enrolling in the study or documented infection.
  • History of organ transplant requiring .
  • History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), unless the inflammation is well controlled.
  • *Inadequate organ function, evidenced by the following laboratory results:
  • (ANC) \< 1000 cells/mm3.
  • Platelet count \< 100,000 cells/mm3.
  • Hemoglobin \< 9 g/dL.
  • Total > 1.5 x the (ULN; unless the subject has documented Gilbert's syndrome).
  • AST (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
  • Alkaline phosphatase (ALP) levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
  • Serum creatinine > 2.0 mg/dL or 177 μmol/L.
  • Albumin \< 2.8 g/dL. Note: Each site should use its own institution's upper limit of normal (ULN) to determine eligibility.
  • *Subjects with ascites requiring paracentesis or pleural effusion requiring thoracentesis.
  • *Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of grade 2 or higher; or serious cardiac arrhythmia requiring medication.
  • *Dyspnea at rest due to complications of advanced or other disease requiring continuous oxygen therapy. Oxygen therapy on an as needed or intermittent basis is allowed.
  • *Current chronic daily treatment (since enrolling in the study) with systemic (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  • *Known to any component of the study medication(s).
  • *Participation in an investigational drug study or history of receiving any investigational treatment or cytotoxic chemotherapy within 14 days prior to dosing for this study, except for hormone-lowering therapy in subjects with hormone-sensitive cancer.
  • *Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  • *Concurrent participation in any interventional clinical trial since enrolling.
  • *Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 24 hours prior to the first dose must be documented before M-CENK is administered to a female subject of childbearing potential.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Subjects newly diagnosed no prior therapy or prior first line treatment

    Cohort 1: Subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment. Cohort 1 may subsequently enroll in cohort 2 part B if they have progressive disease after ≥ 2 prior therapies or if they have progressive disease within 12 months of receiving neoadjuvant or adjuvant chemotherapy and meet the inclusion criteria for cohort 2 part B.

    Other: Apheresis collection of MNCs (part A)

  • Experimental
    Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors

    Cohort 2: Subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies or not a candidate for therapy of proven efficacy for their disease.

    Biological: M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B) · Biological: N-803 (Cohort 2 part B)

Interventions

  • BiologicalM-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)

    M-CENK will be administered up to 10 times weekly via intravenous (IV) infusion starting on study day 1 with a minimum of 7 days between each M-CENK dose. The dose of MCENK will be 0.25 - 0.75 × 10e9 cells per infusion.

  • N-803 15 μg/kg will be administered subcutaneously prior to every other dose of M-CENK for up to 5 doses of N-803.

  • OtherApheresis collection of MNCs (part A)

    Subjects in cohort 1A will participate in apheresis collection of lymphocytes (part A) and will not receive any investigational therapy in this study.

06

What researchers measure

Primary outcomes

  1. Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis.

    \- Safety of apheresis collection as indicated by incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to apheresis, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, or in the case of cytokine release syndrome (CRS), using the specified grading system.

    Time frame: Study Day 1, assessed for up to 1 week

  2. Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by the number of participants with clinically significant laboratory tests.

    \- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to apheresis collection. Hematology test will be performed pre- and post- apheresis collection.

    Time frame: From Baseline/Screening through Study Day 1, assessed for up to 1 day

  3. Primary Objective (cohort 1 and cohort 2, part A subjects): Determine the safety of mononuclear cell (MNC) apheresis collection by number of participants with abnormal vital signs.

    \- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation

    Time frame: From Baseline/Screening through Study Day 1, assessed for up to 28 days

  4. Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of TEAEs and SAEs after the first dose of M-CENK and the first dose of N-803 (M-CENK Dose Number 1)

    \- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using the specified grading system.

    Time frame: From M-CENK Dose Number 1 up to 30 days, assessed for up to 30 days

  5. Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with clinically significant laboratory tests

    \- Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) performed within 1 calendar day prior to first dose.

    Time frame: From M-CENK Dose Number 1, assessed for up to 1 day

  6. Primary Objective (cohort 2, part B subjects): Evaluate the overall safety profile of M-CENK and N-803 for SC administration by the number of participants with abnormal vital signs

    \- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation

    Time frame: From M-CENK Dose Number 1, assessed for up to 1 day

Secondary outcomes

  1. Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs for manufacturing M-CENK cells.

    \- Number of MNCs for manufacturing M-CENK cells

    Time frame: Study Day 1

  2. Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number of MNCs collected and the % of natural killer (NK) cells.

    Number of MNCs collected and the percentage of natural killer (NK) cells (CD56/CD16 positive) after a 2 blood volume apheresis collection.

    Time frame: Study Day 1

  3. Cohort 1 and cohort 2, part A subjects: Evaluate the quantity and quality of the manufactured cells from subjects in cohort 1 vs. cohort 2 by the number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells.

    \- Number, phenotype (CD56/CD16 positive and CD3 positive cells), and function of M-CENK cells as measured by flow cytometry and interferon (IFN) γ production, and cytotoxicity following enrichment and expansion of the NK cells ex vivo.

    Time frame: Study Day 1

  4. Secondary Objective (cohort 1 and cohort 2, part A subjects): Evaluate the quantity and quality of the manufactured investigational cells from subjects in cohort 1 vs. cohort 2 by the number of cryopreserved aliquots of manufactured M-CENK cells.

    \- Number of cryopreserved aliquots of manufactured M-CENK cells.

    Time frame: Study Day 1

  5. Secondary Objective (cohort 2, part B): Evaluate the overall safety profile of up to 10 doses of M-CENK and up to 5 doses of N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of TEAEs and SAEs.

    \- Incidence of TEAEs and SAEs, graded using the NCI CTCAE Version 5.0, or in the case of CRS using a specified grading system.

    Time frame: From M-CENK Dose Number 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months

  6. Cohort 2, part B subjects: Evaluate overall safety profile of up to 10 doses of M-CENK and up to 5 doses of N-803 in subjects with relapsed or refractory (R/R) solid tumors by the number of participants with clinically significant laboratory tests.

    * Clinical lab tests include hematology (CBC w/ differential (5 part) including platelet count) and chemistry panel (BUN, blood urea nitrogen; CBC, complete blood count; RBC, red blood cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase) and will be performed within 1 calendar day prior to dosing. * Vital signs.

    Time frame: From M-CENK Dose Number 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months

  7. Cohort 2, part B: Evaluate the overall safety profile of up to 10 doses of M-CENK and up to 5 doses of N-803 for SC administration in subjects with relapsed or refractory (R/R) solid tumors by the number of of participants with abnormal vital si

    \- Vital signs to include temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation

    Time frame: From M-CENK Dose Number 1 through End of Study (up to 12 months from first dose), assessed for up to 12 months

  8. Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the objective response rate (ORR) by the percentage of subjects that achieve a confirmed complete or partial overall response

    \- ORR will be measured 4 weeks after the first dose of M-CENK then every 8 weeks (± 1 week), and at EOT and EOS, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST) and the percentage of subjects that achieve a confirmed complete or partial overall response will be presented. The 95% confidence interval of the response rate will be presented. Response will be assessed using both RECIST and iRECIST.

    Time frame: From Baseline/Screening through End of Study (up to 12 months from first dose), measured at 4 weeks, every 8 weeks, EOT, EOS

  9. Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the progression-free survival (PFS) by the

    \- PFS will be measured 4 weeks after the first dose of M-CENK then every 8 weeks (± 1 week), and at EOT and EOS by RECIST Version 1.1 and iRECIST and will be evaluated using Kaplan-Meier methods. PFS will be defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first.

    Time frame: From M-CENK Dose Number 1 to the date of disease progression or death (any cause), assessed for up to 12 months

  10. Secondary Objective (cohort 2, part B subjects): Obtain preliminary estimates of efficacy by measuring the overall survival (OS) from the first date of treatment to the date of death.

    Overall Survival will be evaluated using Kaplan-Meier methods. OS will be defined as the time from the date of first treatment to the date of death (any cause). Subjects who are alive at the end of follow-up will be censored at the last known date alive.

    Time frame: From M-CENK Dose Number 1 to the date of death (any cause), assessed for up to 12 months

Other outcomes

  1. Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by frequency and phenotype of immune cells as measured by flow and mass cytometry..

    \- Frequency and phenotype of immune cells as measured by flow and mass cytometry.

    Time frame: From Baseline/Screening through Study Day 1

  2. Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by frequency, number, phenotype, and proliferation of NK cells as measured by flow and mass cytometry.

    \- Frequency, number, phenotype, and proliferation of NK cells as measured by flow and mass cytometry. Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. \- Serum cytokines.

    Time frame: From Baseline/Screening through Study Day 1

  3. Cohort 1/2, part A subjects: Evaluate and compare immune profiles of whole blood and apheresis product by function of NK cells and NK cell receptor profile by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity.

    Exploratory Objective: * Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity. * Serum cytokines.

    Time frame: From Baseline/Screening through Study Day 1

  4. Exploratory Objective (cohort 1 and cohort 2, part A subjects): Evaluate and compare immune profiles of whole blood and apheresis product by measuring serum cytokines.

    \- Serum cytokines.

    Time frame: From Baseline/Screening through Study Day 1

  5. Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by frequency and phenotype of immune cells as measured by flow and mass cytometry.

    \- Frequency and phenotype of immune cells as measured by flow and mass cytometry.

    Time frame: From Baseline/Screening through End of Study, assessed for up to 12 months

  6. Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity.

    \- Function of NK cells and NK cell receptor profile as measured by intracellular staining for cytokines, surface marker staining, and assessments of cytotoxicity.

    Time frame: From Baseline/Screening through End of Study, assessed for up to 12 months

  7. Exploratory Objective (cohort 2, part B subjects): Evaluate whole blood immune profiles by measuring serum cytokines.

    \- Serum cytokines.

    Time frame: From Baseline/Screening through End of Study, assessed for up to 12 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Feb 2026, 55 months.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's 55 months is above that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion May 2026 → Feb 2026 and completion May 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2021
First posted
May 24, 2021
StartActual
Jun 21, 2021
Primary completionActual
Feb 2, 2026was May 2026
CompletionEst.
May 31, 2027was May 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2026→Feb 2, 2026 (actual)
Nov 2, 2026
Study completion
May 31, 2026→May 31, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion May 31, 2026→Feb 2, 2026 (now actual)
    Study completion May 31, 2026→May 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04898543
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
May 24, 2021
Start date
Jun 21, 2021
Primary completion
Feb 2, 2026
Completion
May 31, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Leonard Sender, MD
study director · ImmunityBio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion